The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Evolution of multi-drug resistant hepatitis B virus during sequential therapy
Open accessAbstract
Multi-drug resistant hepatitis B virus (HBV) has been reported in hepatitis B patients who received sequential antiviral therapy. In vitro studies showed that HBV constructs with mutations resistant to lamivudine and adefovir have marked reduction in sensitivity to combination of lamivudine and adefovir, whereas constructs with mutations resistant to either drug remain sensitive to the other drug. We conducted this study to determine whether mutations conferring resistance to multiple antiviral agents co-locate on the same HBV genome in vivo and to describe the evolution of these mutations. Sera from six patients who had been found to have multi-drug resistant HBV mutations to lamivudine + adefovir, lamivudine + hepatitis B immunoglobulin (HBIG), or lamivudine + entecavir on direct sequencing were cloned after nested polymerase chain reaction (PCR). Analysis of 215 clones from 11 samples with multi-drug resistant mutations on direct sequencing showed that 183 (85%) clones had mutations to both therapies on the same genome; 31 clones had lamivudine-resistant mutants only. Clonal analysis of serial samples from three patients showed progressive evolution from all clones with lamivudine-resistant HBV mutations only to mixtures of clones that have multi-drug resistant mutations and clones that have lamivudine-resistant HBV mutations only, and ultimately all clones having multi-drug resistant HBV mutations. In conclusion, mutations conferring resistance to multiple antiviral agents co-locate on the same viral genome, suggesting that combination therapy directed against mutants resistant to each treatment may not be adequate in suppressing multi-drug resistant HBV. De novo combination therapy may prevent the emergence of multi-drug resistant mutants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Vaccine-induced escape mutant of hepatitis B virus
Carman, W. F., Karayiannis, P., Waters, J., Thomas, H. C., Zanetti, A. R., Manzillo, G., & Zuckerman, A. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91874-a · Cited by 1,074
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Self-citationNomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
Stuyver, L. (2001) · Hepatology · doi:10.1053/jhep.2001.22166 · Cited by 382
Lai, C., Rosmawati, M., Lao, J., Van Vlierberghe, H., Anderson, F. H., Thomas, N., & Dehertogh, D. (2002) · Gastroenterology · doi:10.1053/gast.2002.37058 · Cited by 302
Management of Antiviral Resistance in Patients with Chronic Hepatitis B
Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E. B., Liang, T. J., Mutimer, D., Pawlotsky, J.-M., & Zoulim, F. (2004) · Antiviral Therapy · doi:10.1177/135965350400900522 · Cited by 237
Shafer, R. W., Winters, M. A., Palmer, S., & Merigan, T. C. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-11-199806010-00008 · Cited by 197
Torresi, J. (2002) · Journal of Clinical Virology · doi:10.1016/s1386-6532(02)00049-5 · Cited by 193
Bock, C. –., Tillmann, H. L., Torresi, J., Klempnauer, J., Locarnini, S., Manns, M. P., & Trautwein, C. (2002) · Gastroenterology · doi:10.1053/gast.2002.31015 · Cited by 190
Malaguarnera, L., Madeddu, R., Palio, E., Arena, N., & Malaguarnera, M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.040 · Cited by 173
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B
Richman, D. D. (2000) · Hepatology · doi:10.1053/jhep.2000.18194 · Cited by 85
Hepatitis B virus surface mutations associated with infection after liver transplantation
Hawkins, A. E., Gilson, R. J. C., Gilbert, N., Wreghitt, T. G., Gray, J. J., Ahlers-de-Boer, I., Tedder, R. S., & Alexander, G. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80179-6 · Cited by 77
Management of Hepatitis B Patients with Antiviral Resistance
Fung, S. K., & Lok, A. S.-F. (2004) · Antiviral Therapy · doi:10.1177/135965350400900621 · Cited by 41
Self-citationGonzales, M. J., Johnson, E. A., Dupnik, K. M., Imamichi, T., & Shafer, R. W. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200312010-00006 · Cited by 21
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Self-citationChronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Self-citationDomingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Tenney, D. J., Rose, R. E., Baldick, C. J., Pokornowski, K. A., Eggers, B. J., Fang, J., Wichroski, M. J., Xu, D., Yang, J., Wilber, R. B., et al. (2009) · Hepatology · doi:10.1002/hep.22841 · Cited by 804
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & Locarnini, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 706
Metadata
- Authors
- Yim, H. J., Hussain, M., Liu, Y., Wong, S. N., Fung, S. K., & Lok, A. S. F.
- Venue
- Hepatology
- Published
- 2006-09
- Volume
- 44
- Issue
- 3
- Pages
- 703-712
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2049902316
- Cited by
- 253
- References
- 15
- FWCI
- 19.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.